Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia

Background: Breast cancer is highly prevalent worldwide and leads to high health-care costs. HER2-positive subtype represents 30% of all breast cancers and is associated with a poor prognosis. Patients treated with anti-HER2 therapies frequently develop resistance and require pharmacological treatme...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2020

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23699

Acceso en línea:

https://doi.org/10.2147/CEOR.S220726
https://repository.urosario.edu.co/handle/10336/23699

Palabra clave:

Circulating tumor DNA
Docetaxel
Pertuzumab
Trastuzumab
Advanced cancer
Cancer chemotherapy
Cancer resistance
Colombia
Cost effectiveness analysis
DNA determination
Health care cost
Human
Human epidermal growth factor receptor 2 positive breast cancer
Liquid biopsy
Quality adjusted life year
Review
Sensitivity and specificity
Treatment outcome
Biomarkers
Breast cancer
Cost-effectiveness
Liquid biopsy

Rights

License

Abierto (Texto Completo)